(Circulation. 1997;96:3116-3123.)
© 1997 American Heart Association, Inc.
Articles |
Development of Decompensated Dilated Cardiomyopathy Is Associated With Decreased Gene Expression and Activity of the Milrinone-Sensitive cAMP Phosphodiesterase PDE3A
From the Departments of Pathology (C.J.S., R.H., S.R.) and Physiology (D.S., C.H., T.H.H.), New York Medical College, and Department of Surgery (J.-Z.D., R.A.M.), Westchester Medical Center, Valhalla, NY; and Department of Biology (C.H.), Marymount College, Tarrytown, NY.
Background Phosphodiesterase III (PDE3) inhibitors are inotropic agents used to treat congestive heart failure (CHF) and are less effective in patients with severe CHF. Little is known about relative changes in PDE3 activity or gene expression during the evolution of cardiomyopathy.
Methods and Results In the present study, we evaluated temporal changes in PDE3A gene expression before and after pacing-induced CHF in nine mongrel dogs. Three weeks of left ventricular (LV) pacing produced LV end-diastolic pressures of 15±1.7 mm Hg, whereas overt CHF at 4 to 5 weeks was associated with LV end-diastolic pressures of 24±1.7 mm Hg; prepacing values were 6.6±0.6 mm Hg. Total RNA isolated from LV tissues was analyzed on Northern blots; 10 unpaced normal hearts served as tissue controls. Signals for PDE3A mRNAs (7, 8, and 10 kb) or PDE4D (7.6 kb) were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or ribosomal 18S RNA. Before the onset of CHF, PDE3A/GAPDH ratios were not different between the control and 3-week paced groups. In contrast, all PDE3A/GAPDH ratios were selectively reduced by 52%, and PDE3A/18S was reduced by 70% (P<.05) in CHF; PDE4D/GAPDH (or 18S) was unchanged. LV tissues from four control and four CHF dogs were also processed to isolate cytosolic and microsomal membrane protein for cAMP PDE3 activity assays. CHF was associated with a significant 54% reduction (P<.05) in microsomal but not cytosolic PDE3 activity.
Conclusions Selective downregulation of PDE3A may account in part for the ineffectiveness of milrinone in the treatment of severe CHF.
Key Words: heart failure • inotropic agents • pacing
This article has been cited by other articles:
 |
|
 |
|
  A. Abi-Gerges, W. Richter, F. Lefebvre, P. Mateo, A. Varin, C. Heymes, J.-L. Samuel, C. Lugnier, M. Conti, R. Fischmeister, et al. Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on {beta}-Adrenergic cAMP Signals Circ. Res., October 9, 2009; 105(8): 784 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yan, C. L. Miller, and J.-i. Abe Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart Circ. Res., March 2, 2007; 100(4): 489 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Rochais, A. Abi-Gerges, K. Horner, F. Lefebvre, D. M.F. Cooper, M. Conti, R. Fischmeister, and G. Vandecasteele A Specific Pattern of Phosphodiesterases Controls the cAMP Signals Generated by Different Gs-Coupled Receptors in Adult Rat Ventricular Myocytes Circ. Res., April 28, 2006; 98(8): 1081 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ding, J.-i. Abe, H. Wei, Q. Huang, R. A. Walsh, C. A. Molina, A. Zhao, J. Sadoshima, B. C. Blaxall, B. C. Berk, et al. Functional Role of Phosphodiesterase 3 in Cardiomyocyte Apoptosis: Implication in Heart Failure Circulation, May 17, 2005; 111(19): 2469 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xiong, G. R. Ferrier, and S. E. Howlett Diminished Inotropic Response to Amrinone in Ventricular Myocytes from Myopathic Hamsters Is Linked to Depression of High-Gain Ca2+-Induced Ca2+ Release J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 761 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mongillo, T. McSorley, S. Evellin, A. Sood, V. Lissandron, A. Terrin, E. Huston, A. Hannawacker, M. J. Lohse, T. Pozzan, et al. Fluorescence Resonance Energy Transfer-Based Analysis of cAMP Dynamics in Live Neonatal Rat Cardiac Myocytes Reveals Distinct Functions of Compartmentalized Phosphodiesterases Circ. Res., July 9, 2004; 95(1): 67 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto, T. Kobayashi, and K. Kamata Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H283 - H291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, J. H. Traverse, M. Hou, Y. Li, R. Du, and R. J. Bache Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1513 - H1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Tarpey, D. R. Sawmiller, C. Kelly, W. J. Thompson, and M. I. Townsley Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L766 - L773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Dunkerley, D. G. Tilley, D. Palmer, H. Liu, S. L. Jimmo, and D. H. Maurice Reduced Phosphodiesterase 3 Activity and Phosphodiesterase 3A Level in Synthetic Vascular Smooth Muscle Cells: Implications for Use of Phosphodiesterase 3 Inhibitors in Cardiovascular Tissues Mol. Pharmacol., May 1, 2002; 61(5): 1033 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. SENZAKI, C. J. SMITH1, G. J. JUANG, T. ISODA, S. P. MAYER, A. OHLER, N. PAOLOCCI, G. F. TOMASELLI, J. M. HARE, and D. A. KASS Cardiac phosphodiesterase 5 (cGMP-specific) modulates {beta}-adrenergic signaling in vivo and is down-regulated in heart failure FASEB J, August 1, 2001; 15(10): 1718 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yano, M. Kohno, T. Ohkusa, M. Mochizuki, J. Yamada, M. Kohno, T. Hisaoka, K. Ono, T. Tanigawa, S. Kobayashi, et al. Effect of milrinone on left ventricular relaxation and Ca2+ uptake function of cardiac sarcoplasmic reticulum Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1898 - H1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Palmer and D. H. Maurice Dual Expression and Differential Regulation of Phosphodiesterase 3A and Phosphodiesterase 3B in Human Vascular Smooth Muscle: Implications for Phosphodiesterase 3 Inhibition in Human Cardiovascular Tissues Mol. Pharmacol., August 1, 2000; 58(2): 247 - 252. [Abstract] [Full Text]
|
|
|
|
|
|
T. Tanigawa, M. Yano, M. Kohno, T. Yamamoto, T. Hisaoka, K. Ono, T. Ueyama, S. Kobayashi, Y. Hisamatsu, T. Ohkusa, et al. Mechanism of preserved positive lusitropy by cAMP-dependent drugs in heart failure Am J Physiol Heart Circ Physiol, February 1, 2000; 278(2): H313 - H320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sato, K. Asai, S. Okumura, G. Takagi, R. P. Shannon, Y. Fujita-Yamaguchi, Y. Ishikawa, S. F. Vatner, and D. E. Vatner Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1699 - H1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kojda and K. Kottenberg Regulation of basal myocardial function by NO Cardiovasc Res, March 1, 1999; 41(3): 514 - 523. [Full Text] [PDF]
|
|